{"product_id":"the-laboratory-mouse-3rd-edition","title":"The Laboratory Mouse, 3rd Edition","description":"\u003cp\u003e\u003cstrong\u003eBy Mark A. Suckow, Sara Hashway and Kathleen R. Pritchett-Corning\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003eDelivery\u003c\/h3\u003e\n\u003cdiv class=\"gvc-locked-preview\"\u003e\n  \u003cdiv class=\"gvc-locked-icon\"\u003e🔒\u003c\/div\u003e\n  \u003ch3\u003eSample Preview\u003c\/h3\u003e\n  \u003cp\u003eThe full PDF is available after purchase. Instant download. Lifetime access. Read on any device.\u003c\/p\u003e\n  \u003cp class=\"gvc-locked-meta\"\u003eTrusted by 4,000+ veterinary professionals worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cp\u003eInstant digital delivery after purchase. PDF format, compatible with all devices.\u003c\/p\u003e\n\n\u003ch3\u003eTable of Contents\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eContents (p.6)\u003c\/li\u003e\n  \u003cli\u003eContributors (p.12)\u003c\/li\u003e\n  \u003cli\u003ePreface (p.16)\u003c\/li\u003e\n  \u003cli\u003e1 - Historical Foundations (p.22)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.60)\u003c\/li\u003e\n  \u003cli\u003e2 - Taxonomy and Stocks and Strains (p.66)\u003c\/li\u003e\n  \u003cli\u003e1 Standard Inbred Strains (p.72)\u003c\/li\u003e\n  \u003cli\u003e2 Coisogenic and Congenic Strains (p.72)\u003c\/li\u003e\n  \u003cli\u003e3 Consomic or Chromosome Substitution Strains (p.86)\u003c\/li\u003e\n  \u003cli\u003e4 Conplastic Strains (p.86)\u003c\/li\u003e\n  \u003cli\u003e5 Recombinant Inbred Strains (p.87)\u003c\/li\u003e\n  \u003cli\u003e6 Genetically Modified Rats (p.87)\u003c\/li\u003e\n  \u003cli\u003e1 Standard Inbred Strains (p.89)\u003c\/li\u003e\n  \u003cli\u003e2 F1 Hybrids (p.90)\u003c\/li\u003e\n  \u003cli\u003e3 Coisogenic Strains (p.90)\u003c\/li\u003e\n  \u003cli\u003e4 Congenic Strains (p.90)\u003c\/li\u003e\n  \u003cli\u003e4 Consomic Strains (p.90)\u003c\/li\u003e\n  \u003cli\u003e5 Conplastic Strains (p.90)\u003c\/li\u003e\n  \u003cli\u003e6 Recombinant Inbred Strains (p.90)\u003c\/li\u003e\n  \u003cli\u003e7 Genetically Modified Rats (p.90)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.91)\u003c\/li\u003e\n  \u003cli\u003e3 - Translational Potential of Rats in Research (p.96)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.102)\u003c\/li\u003e\n  \u003cli\u003e4 - Functional Anatomy and Physiology (p.110)\u003c\/li\u003e\n  \u003cli\u003e1 Sight and the Eye (p.115)\u003c\/li\u003e\n  \u003cli\u003e2 Olfaction (p.119)\u003c\/li\u003e\n  \u003cli\u003e3 Taste (p.120)\u003c\/li\u003e\n  \u003cli\u003e4 Hearing and Vestibular Function (p.120)\u003c\/li\u003e\n  \u003cli\u003e5 Touch (p.121)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.141)\u003c\/li\u003e\n  \u003cli\u003e5 - Clinical Pathology of the Rat (p.152)\u003c\/li\u003e\n  \u003cli\u003e1 Anemia of Chronic Disease (p.159)\u003c\/li\u003e\n  \u003cli\u003e2 Immune-Mediated Hemolytic Destruction\/Removal of Red Blood Cells (p.159)\u003c\/li\u003e\n  \u003cli\u003e3 Oxidant Injury (p.160)\u003c\/li\u003e\n  \u003cli\u003e4 Plasmodium berghei-Induced Anemia (p.160)\u003c\/li\u003e\n  \u003cli\u003e5 Hereditary Anemias (p.160)\u003c\/li\u003e\n  \u003cli\u003e6 Howell–Jolly Bodies (p.160)\u003c\/li\u003e\n  \u003cli\u003e7 Poikilocytosis (p.160)\u003c\/li\u003e\n  \u003cli\u003e1 Hepatocellular Disease (p.161)\u003c\/li\u003e\n  \u003cli\u003e2 Cholestatic\/Hepatobiliary Disease (p.161)\u003c\/li\u003e\n  \u003cli\u003e3 Inherited Models of Hyperbilirubinemia (p.161)\u003c\/li\u003e\n  \u003cli\u003e4 Hepatocellular Hypertrophy (p.161)\u003c\/li\u003e\n  \u003cli\u003e5 Emerging Biomarkers of Liver Injury (p.162)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.168)\u003c\/li\u003e\n  \u003cli\u003e6 - Reproduction and Breeding (p.176)\u003c\/li\u003e\n  \u003cli\u003e1 Cycle Description (p.177)\u003c\/li\u003e\n  \u003cli\u003e2 Estrous Cycle Stage Identification (p.178)\u003c\/li\u003e\n  \u003cli\u003e3 Estrous Synchronization (p.179)\u003c\/li\u003e\n  \u003cli\u003e1 Breeding (p.187)\u003c\/li\u003e\n  \u003cli\u003e2 Inbred Strains (p.190)\u003c\/li\u003e\n  \u003cli\u003e3 Outbred Stocks (p.190)\u003c\/li\u003e\n  \u003cli\u003e4 Consideration for Genetically Manipulated Lines (p.191)\u003c\/li\u003e\n  \u003cli\u003e1 Animal Identification (p.191)\u003c\/li\u003e\n  \u003cli\u003e2 Record-Keeping Tools (p.191)\u003c\/li\u003e\n  \u003cli\u003e3 Colony Record-Keeping Requirements (p.194)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.194)\u003c\/li\u003e\n  \u003cli\u003e7 - Assisted Reproductive Technologies and Genetic Modifications in Rats (p.200)\u003c\/li\u003e\n  \u003cli\u003e1 Recovery from Female Rats (p.201)\u003c\/li\u003e\n  \u003cli\u003e2 Recovery from Male Rats (p.203)\u003c\/li\u003e\n  \u003cli\u003e1 In Vitro Fertilization (p.205)\u003c\/li\u003e\n  \u003cli\u003e2 Micro-insemination (p.206)\u003c\/li\u003e\n  \u003cli\u003e3 Artificial Insemination (p.207)\u003c\/li\u003e\n  \u003cli\u003e4 In Vitro Embryo Culture (p.207)\u003c\/li\u003e\n  \u003cli\u003e1 Vasectomy (p.208)\u003c\/li\u003e\n  \u003cli\u003e2 Establishment of Pseudopregnant Females (p.208)\u003c\/li\u003e\n  \u003cli\u003e3 Recipient Synchronization (p.209)\u003c\/li\u003e\n  \u003cli\u003e4 Surgical Embryo Transfer (p.209)\u003c\/li\u003e\n  \u003cli\u003e5 Nonsurgical Embryo Transfer (p.209)\u003c\/li\u003e\n  \u003cli\u003e1 Pronuclear Injection (p.214)\u003c\/li\u003e\n  \u003cli\u003e2 Transposition-Mediated Gene Delivery (p.215)\u003c\/li\u003e\n  \u003cli\u003e3 Viral Vector–Mediated Gene Delivery (p.216)\u003c\/li\u003e\n  \u003cli\u003e4 Sperm-Mediated Gene Delivery via Intracytoplasmic Sperm Injection (p.217)\u003c\/li\u003e\n  \u003cli\u003e5 Spermatogonial Stem Cell-Mediated Gene Delivery (p.217)\u003c\/li\u003e\n  \u003cli\u003e1 Embryonic Stem Cell Technology (p.217)\u003c\/li\u003e\n  \u003cli\u003e2 N-Ethyl-N-nitrosourea-Induced Mutagenesis (p.219)\u003c\/li\u003e\n  \u003cli\u003e3 Somatic Cell Nuclear Transfer (p.220)\u003c\/li\u003e\n  \u003cli\u003e4 Gene Knockout Technologies (p.222)\u003c\/li\u003e\n  \u003cli\u003e5 Novel Gene Editing Technologies by Endonucleases (p.223)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.226)\u003c\/li\u003e\n  \u003cli\u003e8 - Analysis of Behavior in Laboratory Rats1 (p.234)\u003c\/li\u003e\n  \u003cli\u003e1 Example of Video-Based Behavioral Analysis (p.236)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.257)\u003c\/li\u003e\n  \u003cli\u003e9 - Nutrition (p.262)\u003c\/li\u003e\n  \u003cli\u003e1 Macrominerals (p.274)\u003c\/li\u003e\n  \u003cli\u003e2 Microminerals (p.281)\u003c\/li\u003e\n  \u003cli\u003e1 Fat-Soluble Vitamins (p.295)\u003c\/li\u003e\n  \u003cli\u003e2 Water-Soluble Vitamins (p.299)\u003c\/li\u003e\n  \u003cli\u003e1 Meal Feeding (p.319)\u003c\/li\u003e\n  \u003cli\u003e2 Pair Feeding (p.319)\u003c\/li\u003e\n  \u003cli\u003e1 Fructose Feeding (p.322)\u003c\/li\u003e\n  \u003cli\u003e2 High-Fat Diets (p.323)\u003c\/li\u003e\n  \u003cli\u003e3 Very High-Fat Diets (p.323)\u003c\/li\u003e\n  \u003cli\u003e4 High-Fat and High-Sugar Diets (p.323)\u003c\/li\u003e\n  \u003cli\u003e5 Metabolic Syndrome Control Diets (p.324)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.334)\u003c\/li\u003e\n  \u003cli\u003e10 - Housing and Environment (p.368)\u003c\/li\u003e\n  \u003cli\u003e1 Isolation Caging (p.374)\u003c\/li\u003e\n  \u003cli\u003e1 Individual Versus Group Housing (p.379)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.416)\u003c\/li\u003e\n  \u003cli\u003e11 - Medical Management and Diagnostic Approaches (p.440)\u003c\/li\u003e\n  \u003cli\u003e1 Random Testing of Resident Animals (p.444)\u003c\/li\u003e\n  \u003cli\u003e2 Targeted Sentinel Programs (p.445)\u003c\/li\u003e\n  \u003cli\u003e3 Vendor Screening (p.447)\u003c\/li\u003e\n  \u003cli\u003e4 Quarantine (p.447)\u003c\/li\u003e\n  \u003cli\u003e5 Screening of Imported Biological Materials (p.448)\u003c\/li\u003e\n  \u003cli\u003e1 General Test Performance Guidelines (p.449)\u003c\/li\u003e\n  \u003cli\u003e2 Testing Methodologies (p.450)\u003c\/li\u003e\n  \u003cli\u003e3 Tissue Preparation (p.457)\u003c\/li\u003e\n  \u003cli\u003e4 Interfacing the Rat Necropsy With the Microscopic Evaluation of Tissues (p.458)\u003c\/li\u003e\n  \u003cli\u003e5 Screening of Tissue by Histology for Lesions of Infectious Disease (p.458)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.466)\u003c\/li\u003e\n  \u003cli\u003e12 - Bacterial, Mycoplasmal, and Mycotic Infections (p.470)\u003c\/li\u003e\n  \u003cli\u003e1 Streptococcus pneumoniae (p.482)\u003c\/li\u003e\n  \u003cli\u003e2 The β-Hemolytic Streptococci (p.484)\u003c\/li\u003e\n  \u003cli\u003e3 Enterococcus sp. Infection (p.485)\u003c\/li\u003e\n  \u003cli\u003e1 Rodentibacter pneumotropicus, Rodentibacter heylii (syn. Pasteurella pneumotropica) (p.509)\u003c\/li\u003e\n  \u003cli\u003e2 Muribacter muris (Actinobacillus muris) (p.512)\u003c\/li\u003e\n  \u003cli\u003e3 Rodentibacter heidelbergensis and Rodentibacter trehalosifermentans (Haemophilus) (p.513)\u003c\/li\u003e\n  \u003cli\u003e1 Klebsiella pneumoniae and Klebsiella oxytoca (p.514)\u003c\/li\u003e\n  \u003cli\u003e2 Bordetella bronchiseptica (p.515)\u003c\/li\u003e\n  \u003cli\u003e3 Staphylococcus aureus (p.516)\u003c\/li\u003e\n  \u003cli\u003e1 Mycoplasma neurolyticum (p.522)\u003c\/li\u003e\n  \u003cli\u003e2 Mycoplasma volis (p.522)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.531)\u003c\/li\u003e\n  \u003cli\u003e13 - Viral Disease (p.560)\u003c\/li\u003e\n  \u003cli\u003e1 Clinical Signs (p.562)\u003c\/li\u003e\n  \u003cli\u003e2 Epidemiology (p.563)\u003c\/li\u003e\n  \u003cli\u003e3 Pathology and Pathogenesis (p.564)\u003c\/li\u003e\n  \u003cli\u003e4 Diagnosis (p.566)\u003c\/li\u003e\n  \u003cli\u003e5 Control and Prevention (p.566)\u003c\/li\u003e\n  \u003cli\u003e6 Interference with Research (p.566)\u003c\/li\u003e\n  \u003cli\u003e1 Clinical Signs (p.569)\u003c\/li\u003e\n  \u003cli\u003e2 Epidemiology (p.569)\u003c\/li\u003e\n  \u003cli\u003e3 Pathology and Pathogenesis (p.570)\u003c\/li\u003e\n  \u003cli\u003e4 Diagnosis (p.572)\u003c\/li\u003e\n  \u003cli\u003e5 Differential Diagnosis (p.572)\u003c\/li\u003e\n  \u003cli\u003e6 Control and Prevention (p.572)\u003c\/li\u003e\n  \u003cli\u003e7 Interference with Research (p.573)\u003c\/li\u003e\n  \u003cli\u003e8 Rat Coronavirus as a Model of Respiratory Viral Infection (p.573)\u003c\/li\u003e\n  \u003cli\u003e9 Emergence of Novel Rat Coronaviruses (p.573)\u003c\/li\u003e\n  \u003cli\u003e1 Sendai Virus (p.575)\u003c\/li\u003e\n  \u003cli\u003e2 Other Paramyxoviruses (p.577)\u003c\/li\u003e\n  \u003cli\u003e1 Cardioviruses (p.577)\u003c\/li\u003e\n  \u003cli\u003e2 Other Picornaviruses (p.578)\u003c\/li\u003e\n  \u003cli\u003e1 Reovirus (p.578)\u003c\/li\u003e\n  \u003cli\u003e2 Rotavirus (p.578)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.579)\u003c\/li\u003e\n  \u003cli\u003e14 - Parasitic Diseases (p.588)\u003c\/li\u003e\n  \u003cli\u003e1 Trypanosoma lewisi (p.589)\u003c\/li\u003e\n  \u003cli\u003e1 Hepatozoon muris (p.590)\u003c\/li\u003e\n  \u003cli\u003e2 Toxoplasma gondii (p.590)\u003c\/li\u003e\n  \u003cli\u003e3 Hammondia hammondi (p.592)\u003c\/li\u003e\n  \u003cli\u003e4 Sarcocystis spp. (p.592)\u003c\/li\u003e\n  \u003cli\u003e5 Frenkelia spp. (p.593)\u003c\/li\u003e\n  \u003cli\u003e1 Trichinella spiralis (p.593)\u003c\/li\u003e\n  \u003cli\u003e2 Calodium hepaticum (p.594)\u003c\/li\u003e\n  \u003cli\u003e3 Trichosomoides crassicauda (p.596)\u003c\/li\u003e\n  \u003cli\u003e4 Gongylonema neoplasticum (p.597)\u003c\/li\u003e\n  \u003cli\u003e1 Taenia taeniaeformis (Cysticercus fasciolaris) (p.597)\u003c\/li\u003e\n  \u003cli\u003e1 Giardia muris (p.598)\u003c\/li\u003e\n  \u003cli\u003e2 Spironucleus (Hexamita) muris (p.599)\u003c\/li\u003e\n  \u003cli\u003e3 Hexamastix muris (p.599)\u003c\/li\u003e\n  \u003cli\u003e4 Chilomastix bettencourti (p.600)\u003c\/li\u003e\n  \u003cli\u003e5 Tritrichomonas muris (p.600)\u003c\/li\u003e\n  \u003cli\u003e6 Tritrichomonas minuta (p.600)\u003c\/li\u003e\n  \u003cli\u003e7 Tetratrichomonas microti (p.600)\u003c\/li\u003e\n  \u003cli\u003e8 Pentatrichomonas hominis (p.600)\u003c\/li\u003e\n  \u003cli\u003e1 Eimeria nieschulzi (p.600)\u003c\/li\u003e\n  \u003cli\u003e2 Eimeria spp. (p.601)\u003c\/li\u003e\n  \u003cli\u003e1 Entamoeba muris (p.601)\u003c\/li\u003e\n  \u003cli\u003e1 Balantidium coli (p.601)\u003c\/li\u003e\n  \u003cli\u003e1 Syphacia muris (p.602)\u003c\/li\u003e\n  \u003cli\u003e2 Syphacia obvelata (p.604)\u003c\/li\u003e\n  \u003cli\u003e3 Aspiculuris tetraptera (p.604)\u003c\/li\u003e\n  \u003cli\u003e4 Heterakis spumosa (p.605)\u003c\/li\u003e\n  \u003cli\u003e1 Rodentolepis nana (p.605)\u003c\/li\u003e\n  \u003cli\u003e2 Hymenolepis diminuta (p.606)\u003c\/li\u003e\n  \u003cli\u003e1 Polyplax spinulosa (p.607)\u003c\/li\u003e\n  \u003cli\u003e1 Radfordia ensifera (p.608)\u003c\/li\u003e\n  \u003cli\u003e2 Notoedres muris (p.608)\u003c\/li\u003e\n  \u003cli\u003e3 Mesostigmatid Mites (p.609)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.612)\u003c\/li\u003e\n  \u003cli\u003e15 -\rNeoplastic Disease (p.620)\u003c\/li\u003e\n  \u003cli\u003e1 Adrenal Cortex (p.647)\u003c\/li\u003e\n  \u003cli\u003e2 Adrenal Medulla (p.647)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.661)\u003c\/li\u003e\n  \u003cli\u003e16 - Metabolic, Traumatic, and Miscellaneous Diseases (p.670)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.703)\u003c\/li\u003e\n  \u003cli\u003e17 - Anesthesia, Analgesia, and Euthanasia (p.718)\u003c\/li\u003e\n  \u003cli\u003e1 Duration of Anesthesia (p.718)\u003c\/li\u003e\n  \u003cli\u003e2 Procedure Invasiveness and Pain Potential (p.718)\u003c\/li\u003e\n  \u003cli\u003e3 Training and Expertise (p.719)\u003c\/li\u003e\n  \u003cli\u003e4 Age and Concurrent Disease (p.719)\u003c\/li\u003e\n  \u003cli\u003e5 Experimental Constraints (p.719)\u003c\/li\u003e\n  \u003cli\u003e1 Health Status (p.719)\u003c\/li\u003e\n  \u003cli\u003e2 Fasting (p.720)\u003c\/li\u003e\n  \u003cli\u003e3 Preanesthetic Drugs (p.720)\u003c\/li\u003e\n  \u003cli\u003e4 Medical Records (p.720)\u003c\/li\u003e\n  \u003cli\u003e1 Anesthesia Recovery (p.720)\u003c\/li\u003e\n  \u003cli\u003e1 Anticholinergics (p.724)\u003c\/li\u003e\n  \u003cli\u003e2 Sedatives and Tranquilizers (p.724)\u003c\/li\u003e\n  \u003cli\u003e1 Anesthesia Machines (p.726)\u003c\/li\u003e\n  \u003cli\u003e2 Ancillary Equipment (p.726)\u003c\/li\u003e\n  \u003cli\u003e3 Waste Gas Scavenging (p.727)\u003c\/li\u003e\n  \u003cli\u003e4 Endotracheal Intubation (p.728)\u003c\/li\u003e\n  \u003cli\u003e1 Pentobarbital (p.732)\u003c\/li\u003e\n  \u003cli\u003e2 Thiopental (p.732)\u003c\/li\u003e\n  \u003cli\u003e3 Methohexital (p.733)\u003c\/li\u003e\n  \u003cli\u003e4 Thiobutabarbital (Inactin) (p.733)\u003c\/li\u003e\n  \u003cli\u003e1 Ketamine (p.733)\u003c\/li\u003e\n  \u003cli\u003e2 Tiletamine\/Zolazepam (p.734)\u003c\/li\u003e\n  \u003cli\u003e1 α-Chloralose (p.736)\u003c\/li\u003e\n  \u003cli\u003e2 Alphaxalone\/Alphadolone (Saffan, Althesin) (p.736)\u003c\/li\u003e\n  \u003cli\u003e3 Chloral Hydrate (p.737)\u003c\/li\u003e\n  \u003cli\u003e4 Propofol (p.737)\u003c\/li\u003e\n  \u003cli\u003e5 Tribromoethanol (p.737)\u003c\/li\u003e\n  \u003cli\u003e6 Urethane (Ethyl Carbamate) (p.737)\u003c\/li\u003e\n  \u003cli\u003e1 Opioids (p.742)\u003c\/li\u003e\n  \u003cli\u003e2 Nonsteroidal Antiinflammatory Drugs (p.745)\u003c\/li\u003e\n  \u003cli\u003e3 Local Anesthetics (p.747)\u003c\/li\u003e\n  \u003cli\u003e4 Miscellaneous Drugs (p.748)\u003c\/li\u003e\n  \u003cli\u003e1 Physical Methods (p.749)\u003c\/li\u003e\n  \u003cli\u003e2 Injectable Methods (p.751)\u003c\/li\u003e\n  \u003cli\u003e3 Inhalation Methods (p.751)\u003c\/li\u003e\n  \u003cli\u003e4 Volatile Anesthetics (p.753)\u003c\/li\u003e\n  \u003cli\u003e5 Neonates\/Fetal Animals (p.753)\u003c\/li\u003e\n  \u003cli\u003e6 Unacceptable Methods (p.754)\u003c\/li\u003e\n  \u003cli\u003e7 Practicalities That Apply to all Methods (p.754)\u003c\/li\u003e\n  \u003cli\u003e8 Summary\/Conclusion (p.754)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.754)\u003c\/li\u003e\n  \u003cli\u003e18 - Care of Surgical and Other Fragile Models (p.766)\u003c\/li\u003e\n  \u003cli\u003e1 Health Status (p.766)\u003c\/li\u003e\n  \u003cli\u003e2 Medical Records (p.766)\u003c\/li\u003e\n  \u003cli\u003e3 Fasting (p.767)\u003c\/li\u003e\n  \u003cli\u003e4 Preanesthetic Drugs (p.767)\u003c\/li\u003e\n  \u003cli\u003e5 Surgical Preparation and Asepsis (p.767)\u003c\/li\u003e\n  \u003cli\u003e1 Monitoring (p.769)\u003c\/li\u003e\n  \u003cli\u003e2 Intraoperative Support (p.771)\u003c\/li\u003e\n  \u003cli\u003e1 Anesthesia Recovery (p.772)\u003c\/li\u003e\n  \u003cli\u003e2 Surgical Recovery (p.773)\u003c\/li\u003e\n  \u003cli\u003e1 Dilated Cardiomyopathy (p.776)\u003c\/li\u003e\n  \u003cli\u003e2 Hypertension and Stroke (p.776)\u003c\/li\u003e\n  \u003cli\u003e3 Myocardial Infarction (p.777)\u003c\/li\u003e\n  \u003cli\u003e1 Diabetes Mellitus and Metabolic Syndrome (p.777)\u003c\/li\u003e\n  \u003cli\u003e2 Hypoadrenocorticism (p.777)\u003c\/li\u003e\n  \u003cli\u003e3 Hypothyroidism\/Hypoparathyroidism (p.778)\u003c\/li\u003e\n  \u003cli\u003e4 Osteoporosis (p.778)\u003c\/li\u003e\n  \u003cli\u003e1 Rheumatoid Arthritis (p.779)\u003c\/li\u003e\n  \u003cli\u003e1 Neurodegenerative Disease (p.779)\u003c\/li\u003e\n  \u003cli\u003e2 Spinal Cord and Peripheral Nerve Injury (p.780)\u003c\/li\u003e\n  \u003cli\u003e1 Cranial Implants (p.782)\u003c\/li\u003e\n  \u003cli\u003e2 Chronic Indwelling Catheters and Vascular Access Ports (p.782)\u003c\/li\u003e\n  \u003cli\u003e3 Osmotic Pumps (p.783)\u003c\/li\u003e\n  \u003cli\u003e4 Telemetry Devices (p.783)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.783)\u003c\/li\u003e\n  \u003cli\u003e19 - General Experimental Techniques (p.790)\u003c\/li\u003e\n  \u003cli\u003e1 Cardiac Puncture (p.796)\u003c\/li\u003e\n  \u003cli\u003e2 Orbital Plexus (p.796)\u003c\/li\u003e\n  \u003cli\u003e3 Dorsal Metatarsal Vein (p.797)\u003c\/li\u003e\n  \u003cli\u003e4 Saphenous Vein (p.798)\u003c\/li\u003e\n  \u003cli\u003e5 Tail Vein (p.798)\u003c\/li\u003e\n  \u003cli\u003e6 Jugular Vein (p.799)\u003c\/li\u003e\n  \u003cli\u003e7 Carotid Artery (p.800)\u003c\/li\u003e\n  \u003cli\u003e8 Decapitation (p.800)\u003c\/li\u003e\n  \u003cli\u003e9 Other Techniques (p.801)\u003c\/li\u003e\n  \u003cli\u003e1 Manual Expression and Free Catch (p.801)\u003c\/li\u003e\n  \u003cli\u003e2 Cystocentesis (p.801)\u003c\/li\u003e\n  \u003cli\u003e3 Catheterization, Cystotomy, and Cannulation (p.801)\u003c\/li\u003e\n  \u003cli\u003e4 Other Methods (p.802)\u003c\/li\u003e\n  \u003cli\u003e1 Ova and Embryos (p.806)\u003c\/li\u003e\n  \u003cli\u003e2 Vaginal Fluids and Cells (p.806)\u003c\/li\u003e\n  \u003cli\u003e3 Milk (p.807)\u003c\/li\u003e\n  \u003cli\u003e1 Direct Collection (p.809)\u003c\/li\u003e\n  \u003cli\u003e2 Cannulation Techniques (p.810)\u003c\/li\u003e\n  \u003cli\u003e3 Removal of Salivary Glands at Necropsy (p.810)\u003c\/li\u003e\n  \u003cli\u003e1 Gavage (p.810)\u003c\/li\u003e\n  \u003cli\u003e2 Pilling (p.811)\u003c\/li\u003e\n  \u003cli\u003e3 Surgical Cannulation (p.811)\u003c\/li\u003e\n  \u003cli\u003e4 Syringe Feeding (p.811)\u003c\/li\u003e\n  \u003cli\u003e5 Medicated Diets or Food Treats (p.811)\u003c\/li\u003e\n  \u003cli\u003e6 Administration in Drinking Water (p.812)\u003c\/li\u003e\n  \u003cli\u003e1 Lateral Tail Vein (p.812)\u003c\/li\u003e\n  \u003cli\u003e2 Infusion via Chronic Indwelling Catheters (p.812)\u003c\/li\u003e\n  \u003cli\u003e3 Lingual Vein (p.813)\u003c\/li\u003e\n  \u003cli\u003e4 Dorsal Vein of the Penis (p.813)\u003c\/li\u003e\n  \u003cli\u003e5 Other Intravenous Injection Techniques (p.814)\u003c\/li\u003e\n  \u003cli\u003e1 Blood Pressure Determination (p.816)\u003c\/li\u003e\n  \u003cli\u003e2 Blood and Plasma Volume Determination (p.816)\u003c\/li\u003e\n  \u003cli\u003e3 Electrocardiographic Techniques (p.817)\u003c\/li\u003e\n  \u003cli\u003e1 Electroencephalography (p.817)\u003c\/li\u003e\n  \u003cli\u003e2 Peripheral Nerve Conduction Velocity (p.817)\u003c\/li\u003e\n  \u003cli\u003e3 Evoked Potentials (p.817)\u003c\/li\u003e\n  \u003cli\u003e4 Brain Imaging (p.818)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.819)\u003c\/li\u003e\n  \u003cli\u003e20 - Integrating Biology With Rat Genomic Tools (p.830)\u003c\/li\u003e\n  \u003cli\u003e1 PhenoMiner (p.838)\u003c\/li\u003e\n  \u003cli\u003e2 OLGA (p.838)\u003c\/li\u003e\n  \u003cli\u003e3 Variant Visualizer (p.838)\u003c\/li\u003e\n  \u003cli\u003e4 Pathways (p.838)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.840)\u003c\/li\u003e\n  \u003cli\u003e21 - Gnotobiotics and the Microbiome (p.846)\u003c\/li\u003e\n  \u003cli\u003e1 LOBUND (p.856)\u003c\/li\u003e\n  \u003cli\u003e2 Karolinska Institutet (p.857)\u003c\/li\u003e\n  \u003cli\u003e3 University of Wisconsin (p.857)\u003c\/li\u003e\n  \u003cli\u003e4 Commercial Suppliers (p.857)\u003c\/li\u003e\n  \u003cli\u003e5 Others (p.857)\u003c\/li\u003e\n  \u003cli\u003e1 Colon Cancer (p.858)\u003c\/li\u003e\n  \u003cli\u003e2 Breast and Prostate Cancers (p.858)\u003c\/li\u003e\n  \u003cli\u003e3 Leukemia (p.858)\u003c\/li\u003e\n  \u003cli\u003e4 Urethral Cancer (p.858)\u003c\/li\u003e\n  \u003cli\u003e5 Endocrine Cancer (p.858)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.862)\u003c\/li\u003e\n  \u003cli\u003e22 - Toxicology (p.868)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.879)\u003c\/li\u003e\n  \u003cli\u003e23 - Embryology and Teratology (p.882)\u003c\/li\u003e\n  \u003cli\u003e1 Fertilization (p.882)\u003c\/li\u003e\n  \u003cli\u003e2 Cleavage\/Morula Formation (p.883)\u003c\/li\u003e\n  \u003cli\u003e3 Blastocyst (p.884)\u003c\/li\u003e\n  \u003cli\u003e4 Yolk Sac Placenta Development (p.885)\u003c\/li\u003e\n  \u003cli\u003e1 Neurulation and Early Central Nervous System Development (p.888)\u003c\/li\u003e\n  \u003cli\u003e2 Somite Formation (p.890)\u003c\/li\u003e\n  \u003cli\u003e3 Cardiovascular System (p.890)\u003c\/li\u003e\n  \u003cli\u003e4 Urogenital System (p.893)\u003c\/li\u003e\n  \u003cli\u003e5 Craniofacial Development (p.894)\u003c\/li\u003e\n  \u003cli\u003e6 Limb Development (p.896)\u003c\/li\u003e\n  \u003cli\u003e1 Dose Selection (p.899)\u003c\/li\u003e\n  \u003cli\u003e2 Routes of Administration, Frequency of Dosing, and Dose Volume (p.899)\u003c\/li\u003e\n  \u003cli\u003e3 In Vivo Observations (p.900)\u003c\/li\u003e\n  \u003cli\u003e4 Toxicokinetic Parameters (p.900)\u003c\/li\u003e\n  \u003cli\u003e5 Dam Necropsy and Collection of Fetal and Placental Data (p.900)\u003c\/li\u003e\n  \u003cli\u003e6 Fetal Evaluations (p.901)\u003c\/li\u003e\n  \u003cli\u003e7 Evaluation Criteria (p.902)\u003c\/li\u003e\n  \u003cli\u003e8 Statistical Analysis (p.903)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.904)\u003c\/li\u003e\n  \u003cli\u003e24 - Rat Immunology (p.910)\u003c\/li\u003e\n  \u003cli\u003e1 Organs and Tissues of the Rat's Immune System (p.912)\u003c\/li\u003e\n  \u003cli\u003e2 Cells and Intercellular Messengers of the Rat's Immune System (p.915)\u003c\/li\u003e\n  \u003cli\u003e3 Intersections Between Adaptive and Innate Immunity (p.920)\u003c\/li\u003e\n  \u003cli\u003e1 Biobreeding Diabetes-Prone Rats (BBDP) (p.923)\u003c\/li\u003e\n  \u003cli\u003e2 Long-Evans Cinnamon Rats (LEC) (p.923)\u003c\/li\u003e\n  \u003cli\u003e3 Brown Norway Rats (BN) (p.923)\u003c\/li\u003e\n  \u003cli\u003e4 Lewis Rats (LEW) (p.924)\u003c\/li\u003e\n  \u003cli\u003e5 Athymic Nude Rat (p.924)\u003c\/li\u003e\n  \u003cli\u003e6 IL12g-deficient and F344-SCID gamma Rats (p.924)\u003c\/li\u003e\n  \u003cli\u003e7 Humanized Immune System Rats (p.925)\u003c\/li\u003e\n  \u003cli\u003e1 Cardiac Transplantation (p.925)\u003c\/li\u003e\n  \u003cli\u003e2 Kidney Transplantation (p.927)\u003c\/li\u003e\n  \u003cli\u003e3 Liver Transplantation (p.929)\u003c\/li\u003e\n  \u003cli\u003e4 Lung Transplantation (p.931)\u003c\/li\u003e\n  \u003cli\u003e5 Vascularized Composite Allografts (p.931)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.932)\u003c\/li\u003e\n  \u003cli\u003e25 - Cardiovascular Research (p.946)\u003c\/li\u003e\n  \u003cli\u003e1 Myocyte Orientation (p.950)\u003c\/li\u003e\n  \u003cli\u003e2 Cellular Composition (p.951)\u003c\/li\u003e\n  \u003cli\u003e3 Myocyte Dimensions (p.951)\u003c\/li\u003e\n  \u003cli\u003e4 Myocyte Structural Changes During Growth (p.952)\u003c\/li\u003e\n  \u003cli\u003e1 Historical Development (p.958)\u003c\/li\u003e\n  \u003cli\u003e2 Hypertension and Complicating Lesions (p.958)\u003c\/li\u003e\n  \u003cli\u003e3 Mechanism of Hypertension in Spontaneously Hypertensive Rats (p.960)\u003c\/li\u003e\n  \u003cli\u003e4 Pathogenesis of Hypertrophy (p.960)\u003c\/li\u003e\n  \u003cli\u003e1 Spontaneously Hypertensive Stroke Prone Rats (p.960)\u003c\/li\u003e\n  \u003cli\u003e2 Spontaneously Hypertensive Obese Rats (p.961)\u003c\/li\u003e\n  \u003cli\u003e3 Spontaneously Hypertensive Heart Failure Rats (p.961)\u003c\/li\u003e\n  \u003cli\u003e1 Exercise Induced (p.966)\u003c\/li\u003e\n  \u003cli\u003e2 Aortic Banding (p.966)\u003c\/li\u003e\n  \u003cli\u003e3 Volume Overload (p.966)\u003c\/li\u003e\n  \u003cli\u003e4 Thyroxine (p.967)\u003c\/li\u003e\n  \u003cli\u003e5 Isoproterenol (p.967)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.973)\u003c\/li\u003e\n  \u003cli\u003e26 - Rat Models of Alcohol Use Disorder (p.986)\u003c\/li\u003e\n  \u003cli\u003e1 Bottle Free-choice: Voluntary Oral Alcohol Intake and the Deprivation Effect (p.992)\u003c\/li\u003e\n  \u003cli\u003e2 Continuous, Intermittent, and Limited Access Models (p.993)\u003c\/li\u003e\n  \u003cli\u003e3 Alcohol Liquid Diet (p.993)\u003c\/li\u003e\n  \u003cli\u003e4 Alcohol Vapor Exposure (p.993)\u003c\/li\u003e\n  \u003cli\u003e1 Operant Alcohol Self-Administration (p.994)\u003c\/li\u003e\n  \u003cli\u003e2 Progressive-Ratio Schedules of Reinforcement (p.995)\u003c\/li\u003e\n  \u003cli\u003e3 Self-Administration Despite Punishment (p.995)\u003c\/li\u003e\n  \u003cli\u003e4 Other Schedules of Reinforcement (p.995)\u003c\/li\u003e\n  \u003cli\u003e5 Reinstatement of Alcohol Seeking (p.996)\u003c\/li\u003e\n  \u003cli\u003e1 Conditioned Place Preference (p.998)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.1000)\u003c\/li\u003e\n  \u003cli\u003e27 - Rat Models of Obesity, Metabolic Syndrome, and Diabetes (p.1006)\u003c\/li\u003e\n  \u003cli\u003e1 Single-Nutrition-Enriched Foods: Fat, Sucrose, and Fructose (p.1007)\u003c\/li\u003e\n  \u003cli\u003e2 Dietary Variety: Cafeteria Diet (p.1007)\u003c\/li\u003e\n  \u003cli\u003e1 Obese Zucker Rat (p.1008)\u003c\/li\u003e\n  \u003cli\u003e2 Wistar-Kyoto Fatty Rat (p.1009)\u003c\/li\u003e\n  \u003cli\u003e3 Obese Spontaneously Hypertensive Rat (p.1009)\u003c\/li\u003e\n  \u003cli\u003e4 Otsuka Long-Evans Tokushima Fatty Rat (p.1009)\u003c\/li\u003e\n  \u003cli\u003e1 The University of California Davis Type 2 Diabetes Mellitus Rat (p.1009)\u003c\/li\u003e\n  \u003cli\u003e2 Obese Spontaneously Hypertensive Rat\/Koletsky Rat (p.1009)\u003c\/li\u003e\n  \u003cli\u003e3 Nile Grass Rat (p.1010)\u003c\/li\u003e\n  \u003cli\u003e4 SHRSP Fatty (fa\/fa) Rat (p.1010)\u003c\/li\u003e\n  \u003cli\u003e5 Dahl S.Z-Lepr(fa)\/Lepr(fa) Rat (p.1010)\u003c\/li\u003e\n  \u003cli\u003e1 High-Fat Diet (p.1010)\u003c\/li\u003e\n  \u003cli\u003e2 High-Sucrose\/High Fat Diet (p.1010)\u003c\/li\u003e\n  \u003cli\u003e3 High-Sucrose and High-Fructose Diets (p.1010)\u003c\/li\u003e\n  \u003cli\u003e4 Cafeteria Diet (p.1011)\u003c\/li\u003e\n  \u003cli\u003e1 Chemical Ablation Models of T1DM (p.1012)\u003c\/li\u003e\n  \u003cli\u003e2 Models of Spontaneous T1DM (p.1012)\u003c\/li\u003e\n  \u003cli\u003e3 Other Models of Induced T1DM (p.1013)\u003c\/li\u003e\n  \u003cli\u003e1 Induced Models of T2DM (p.1014)\u003c\/li\u003e\n  \u003cli\u003e2 Spontaneous Obese Models of T2DM (p.1014)\u003c\/li\u003e\n  \u003cli\u003e3 Nonobese Models of T2DM (p.1015)\u003c\/li\u003e\n  \u003cli\u003e1 Placental Insufficiency Models (p.1016)\u003c\/li\u003e\n  \u003cli\u003e2 Models Involving Maternal and Fetal Malnutrition (p.1016)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.1017)\u003c\/li\u003e\n  \u003cli\u003e28 - The Rat in Neuroscience Research (p.1022)\u003c\/li\u003e\n  \u003cli\u003e1 Brain Regions and Neurotransmitters Involved in Anxiety and Depression (p.1022)\u003c\/li\u003e\n  \u003cli\u003e2 Behavioral Tests for Evaluating Anxiety and Depression (p.1023)\u003c\/li\u003e\n  \u003cli\u003e3 Rat Models of Anxiety and Depression (p.1024)\u003c\/li\u003e\n  \u003cli\u003e1 Brain Regions and Neurotransmitters Involved in PTSD (p.1025)\u003c\/li\u003e\n  \u003cli\u003e2 Models of PTSD (p.1026)\u003c\/li\u003e\n  \u003cli\u003e1 Intracerebroventricular Streptozotocin Injection (p.1028)\u003c\/li\u003e\n  \u003cli\u003e2 Aluminum Chloride (p.1029)\u003c\/li\u003e\n  \u003cli\u003e3 Aβ Intracerebral Infusions (p.1030)\u003c\/li\u003e\n  \u003cli\u003e4 Adeno-Associated Virus Transduction With β-Amyloid Variants (p.1030)\u003c\/li\u003e\n  \u003cli\u003e5 Transgenic Rat (TgF344-AD) (p.1030)\u003c\/li\u003e\n  \u003cli\u003e6 Sex Differences in AD Pathology in Rats (p.1031)\u003c\/li\u003e\n  \u003cli\u003e1 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (p.1031)\u003c\/li\u003e\n  \u003cli\u003e2 6-Hydroxydopamine (p.1031)\u003c\/li\u003e\n  \u003cli\u003e3 Rotenone (p.1031)\u003c\/li\u003e\n  \u003cli\u003e4 Paraquat (p.1032)\u003c\/li\u003e\n  \u003cli\u003e5 Sex Differences in Rat Models of PD (p.1032)\u003c\/li\u003e\n  \u003cli\u003e1 Chemically Induced Inflammatory Pain (p.1034)\u003c\/li\u003e\n  \u003cli\u003e2 Cancer-Induced Bone Pain (p.1034)\u003c\/li\u003e\n  \u003cli\u003e3 Migraine (p.1035)\u003c\/li\u003e\n  \u003cli\u003e4 Neuropathic Pain (p.1035)\u003c\/li\u003e\n  \u003cli\u003e5 Osteoarthritis (p.1035)\u003c\/li\u003e\n  \u003cli\u003e6 Visceral Pain (p.1035)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.1036)\u003c\/li\u003e\n  \u003cli\u003e29 - Rat Models of Central Nervous System Injury (p.1042)\u003c\/li\u003e\n  \u003cli\u003e1 Contusion (p.1046)\u003c\/li\u003e\n  \u003cli\u003e2 Compression (p.1049)\u003c\/li\u003e\n  \u003cli\u003e3 Distraction and Dislocation (p.1051)\u003c\/li\u003e\n  \u003cli\u003e4 Transection\/Laceration (p.1052)\u003c\/li\u003e\n  \u003cli\u003e5 Other Techniques (p.1054)\u003c\/li\u003e\n  \u003cli\u003e1 Motor Function (p.1055)\u003c\/li\u003e\n  \u003cli\u003e2 Sensory Testing and Neuropathic Pain (p.1057)\u003c\/li\u003e\n  \u003cli\u003e3 Impact of Environmental Enrichment (p.1058)\u003c\/li\u003e\n  \u003cli\u003e4 Electrophysiology (p.1058)\u003c\/li\u003e\n  \u003cli\u003e5 Autonomic Testing (p.1059)\u003c\/li\u003e\n  \u003cli\u003e6 Imaging (p.1060)\u003c\/li\u003e\n  \u003cli\u003e7 Microscopic Tissue Analysis (p.1060)\u003c\/li\u003e\n  \u003cli\u003e1 Preinjury (p.1061)\u003c\/li\u003e\n  \u003cli\u003e2 Injury Procedure (p.1062)\u003c\/li\u003e\n  \u003cli\u003e3 Postinjury (p.1063)\u003c\/li\u003e\n  \u003cli\u003e1 Fluid Percussion Injury—Lateral and Midline (p.1066)\u003c\/li\u003e\n  \u003cli\u003e2 Controlled Cortical Impact (p.1067)\u003c\/li\u003e\n  \u003cli\u003e3 Penetrating (p.1068)\u003c\/li\u003e\n  \u003cli\u003e4 Weight Drop (p.1069)\u003c\/li\u003e\n  \u003cli\u003e5 Blast TBI (p.1070)\u003c\/li\u003e\n  \u003cli\u003e6 Rotation (p.1071)\u003c\/li\u003e\n  \u003cli\u003e1 Behavioral Tests (p.1072)\u003c\/li\u003e\n  \u003cli\u003e1 Preinjury (p.1077)\u003c\/li\u003e\n  \u003cli\u003e2 Injury Procedure (p.1077)\u003c\/li\u003e\n  \u003cli\u003e3 Postinjury (p.1078)\u003c\/li\u003e\n  \u003cli\u003e1 Caution in Interpreting Results from Rodent Studies and Extrapolating to Human Conditions (p.1078)\u003c\/li\u003e\n  \u003cli\u003e2 Common Data Elements and Standardization of Practice in the Field (p.1079)\u003c\/li\u003e\n  \u003cli\u003e3 Moving Forward: The Role of Rodent Models in CNS Trauma Research (p.1079)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.1079)\u003c\/li\u003e\n  \u003cli\u003e30 - Use of the Rat as a Model in Regenerative Medicine (p.1096)\u003c\/li\u003e\n  \u003cli\u003e1 Surgical (p.1097)\u003c\/li\u003e\n  \u003cli\u003e2 Chemical (p.1098)\u003c\/li\u003e\n  \u003cli\u003e3 Genetic (p.1099)\u003c\/li\u003e\n  \u003cli\u003e1 Recent Advances: Hepatocyte Transplantation (p.1099)\u003c\/li\u003e\n  \u003cli\u003e2 Emerging Therapies (p.1100)\u003c\/li\u003e\n  \u003cli\u003e1 Myocardial Infarction (p.1101)\u003c\/li\u003e\n  \u003cli\u003e2 Congenital Defects (p.1101)\u003c\/li\u003e\n  \u003cli\u003e1 Contusion (p.1105)\u003c\/li\u003e\n  \u003cli\u003e2 Compression (p.1105)\u003c\/li\u003e\n  \u003cli\u003e3 Transections (p.1105)\u003c\/li\u003e\n  \u003cli\u003e4 Incomplete Transection (p.1105)\u003c\/li\u003e\n  \u003cli\u003e5 Complete Transection (p.1105)\u003c\/li\u003e\n  \u003cli\u003e1 Motor Training (p.1106)\u003c\/li\u003e\n  \u003cli\u003e2 Electrical Epidural Stimulation (p.1107)\u003c\/li\u003e\n  \u003cli\u003e3 Cell Therapy (p.1108)\u003c\/li\u003e\n  \u003cli\u003e4 Biomaterials (p.1108)\u003c\/li\u003e\n  \u003cli\u003e5 Future Directions (p.1108)\u003c\/li\u003e\n  \u003cli\u003e1 Behavioral Alterations in the 6-OHDA Model (p.1110)\u003c\/li\u003e\n  \u003cli\u003e1 Endochondral Ossification (p.1113)\u003c\/li\u003e\n  \u003cli\u003e2 Intramembranous Ossification (p.1114)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.1116)\u003c\/li\u003e\n  \u003cli\u003e31 - Rat Models of Infectious Disease (p.1126)\u003c\/li\u003e\n  \u003cli\u003e1 Arboviral Encephalitis: Flaviviruses in Infant Rats (p.1129)\u003c\/li\u003e\n  \u003cli\u003e2 Rabies (p.1129)\u003c\/li\u003e\n  \u003cli\u003e1 General Considerations (p.1133)\u003c\/li\u003e\n  \u003cli\u003e2 Respiratory Syncytial Virus (p.1133)\u003c\/li\u003e\n  \u003cli\u003e3 Influenza (p.1134)\u003c\/li\u003e\n  \u003cli\u003e4 Metapneumovirus (p.1135)\u003c\/li\u003e\n  \u003cli\u003e1 Contact Lens Keratitis (p.1141)\u003c\/li\u003e\n  \u003cli\u003e2 Vascular and Soft Tissue Implants (p.1141)\u003c\/li\u003e\n  \u003cli\u003e3 Periodontitis (p.1142)\u003c\/li\u003e\n  \u003cli\u003e1 Oral and Invasive Candidiasis (p.1143)\u003c\/li\u003e\n  \u003cli\u003e2 Hepatitis C and Hepatitis C-Like Viruses (p.1143)\u003c\/li\u003e\n  \u003cli\u003e1 Pyelonephritis (p.1144)\u003c\/li\u003e\n  \u003cli\u003e2 Epididymitis (p.1144)\u003c\/li\u003e\n  \u003cli\u003e3 Prostatitis (p.1145)\u003c\/li\u003e\n  \u003cli\u003e4 Vaginosis\/Vaginitis (p.1145)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.1147)\u003c\/li\u003e\n  \u003cli\u003eIndex (p.1154)\u003c\/li\u003e\n  \u003cli\u003e\u003cem\u003e... and 822 more chapters\u003c\/em\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cdiv style=\"margin:20px 0;\"\u003e\n\u003ch3\u003ePreview This Book (First 20 Pages)\u003c\/h3\u003e\n\n\u003cp style=\"font-size:12px;color:#666;margin-top:4px;\"\u003eScroll through the preview above to see the first 20 pages of this book.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin:20px 0;\"\u003e\n\u003ch3\u003ePreview This Book (First 20 Pages)\u003c\/h3\u003e\n\n\u003cp style=\"font-size:12px;color:#666;margin-top:4px;\"\u003eScroll through the preview above to see the first 20 pages of this book.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003e🔗 Download Link:\u003c\/strong\u003e \u003c\/p\u003e","brand":"Global Vet \u0026 Co","offers":[{"title":"Default Title","offer_id":51245636288827,"sku":null,"price":168.0,"currency_code":"HKD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0948\/3062\/5083\/files\/the-laboratory-mouse-3rd-edition_HD.jpg?v=1780514552","url":"https:\/\/globalvetco.com\/products\/the-laboratory-mouse-3rd-edition","provider":"Global Vet \u0026 Co Ltd","version":"1.0","type":"link"}